Canadian patent application relating to uTRACE[®] is ready for allowance in Canada
The Canadian Intellectual Property Office has announced that Curasight’s Canadian patent application CA 2,903,261 is ready for allowance and the patent will be issued. This patent application relates to Curasight’s imaging technology relating to uTRACE® (imaging agent 68Ga-NOTA-AE105) and uses thereof until 2034.
The company is a pioneer in the field of exploiting the Positron Emissions Tomography (PET) imaging platform targeting the receptor uPAR, which is a known biomarker of cancer aggressiveness, to be used for improved diagnosis in multiple types of cancer.
Curasight has developed a novel radiopharmaceutical platform (uTRACE®) for improved diagnose, risk stratification and treatment monitoring for cancer patients based on uPAR PET Imaging within different cancer indications.
More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
“The validation of this Canadian patent application has now been officially confirmed by the Canadian Intellectual Property Office. For Curasight this is a major milestone for the further development of uTRACE® and of major strategic importance for our strategy in the North American market” says CEO Ulrich Krasilnikoff.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60
This information is such information that Curasight A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 22 October, 2020.
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.